MDT

96.03

+0.43%↑

VEEV

285.4

+0.85%↑

A

143.12

+0.86%↑

HQY

93.19

+2.19%↑

TLRY

1.57

+1.29%↑

MDT

96.03

+0.43%↑

VEEV

285.4

+0.85%↑

A

143.12

+0.86%↑

HQY

93.19

+2.19%↑

TLRY

1.57

+1.29%↑

MDT

96.03

+0.43%↑

VEEV

285.4

+0.85%↑

A

143.12

+0.86%↑

HQY

93.19

+2.19%↑

TLRY

1.57

+1.29%↑

MDT

96.03

+0.43%↑

VEEV

285.4

+0.85%↑

A

143.12

+0.86%↑

HQY

93.19

+2.19%↑

TLRY

1.57

+1.29%↑

MDT

96.03

+0.43%↑

VEEV

285.4

+0.85%↑

A

143.12

+0.86%↑

HQY

93.19

+2.19%↑

TLRY

1.57

+1.29%↑

Search

Day One Biopharmaceuticals Inc

Aperta

SettoreSettore sanitario

7.37 2.36

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

7.27

Massimo

7.51

Metriche Chiave

By Trading Economics

Entrata

5.7M

-30M

Vendite

3.1M

34M

Margine di Profitto

-89.424

Dipendenti

182

EBITDA

5.2M

-35M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+233.33% upside

Dividendi

By Dow Jones

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

54M

736M

Apertura precedente

5.01

Chiusura precedente

7.37

Notizie sul Sentiment di mercato

By Acuity

50%

50%

141 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 ott 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 ott 2025, 23:37 UTC

Discorsi di Mercato

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 ott 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 ott 2025, 23:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 ott 2025, 23:09 UTC

Discorsi di Mercato

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 ott 2025, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 ott 2025, 22:30 UTC

Utili

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 ott 2025, 22:18 UTC

Discorsi di Mercato

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 ott 2025, 21:50 UTC

Discorsi di Mercato

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 ott 2025, 21:15 UTC

Discorsi di Mercato

Investors Need to Change Narrative Toward Scales -- Market Talk

19 ott 2025, 19:34 UTC

Acquisizioni, Fusioni, Takeovers

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 ott 2025, 19:34 UTC

Acquisizioni, Fusioni, Takeovers

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 ott 2025, 19:33 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 ott 2025, 19:32 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 ott 2025, 19:32 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 ott 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 ott 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 ott 2025, 16:29 UTC

Utili

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 ott 2025, 11:14 UTC

Utili

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 ott 2025, 11:14 UTC

Utili

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 ott 2025, 11:14 UTC

Utili

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 ott 2025, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

17 ott 2025, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 ott 2025, 22:15 UTC

Discorsi di Mercato

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 ott 2025, 21:15 UTC

Discorsi di Mercato

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Confronto tra pari

Modifica del prezzo

Day One Biopharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

233.33% in crescita

Previsioni per 12 mesi

Media 24 USD  233.33%

Alto 34 USD

Basso 16 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

8

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

6.26 / 7.47Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

141 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat